Rep. Bill Hugin’s Past Role at Celgene Linked to Thalidomide’s Re‑launch as Cancer Drug

Rep. Bill Hugin’s Past Role at Celgene Linked to Thalidomide’s Re‑launch as Cancer Drug The fragment suggests that former Congressman Bill Hugin worked at Celgene during the company's controversial effort to market thalidomide (Thalomid) for leprosy and cancer. It hints at possible conflicts of interest or undisclosed influence but provides no concrete dates, transactions, or evidence of wrongdoing, limiting its immediate investigative value. Key insights: Bill Hugin joined Celgene in June 1999, shortly after the firm began repurposing thalidomide.; Celgene pursued a highly regulated, limited‑prescription distribution system for thalidomide, citing safety concerns.; The text references a “once‑notorious drug” becoming a “lucrative cancer weapon,” implying significant profit potential.